arrow
M

Massimo Milani

cantabria labs difa cooper
H指数:33
被引数:4,512

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A 50+Sunscreen Containing Polypodium Leucotomos Extract, Ellagic Acid, and Niacinamide in Facial Melasma and Photoaging-Related Hyperpigmentation: A Pilot Observational Study Using Line-Field Confocal Optical Coherence Tomography

含pteris leucotomos提取物、鞣花酸和烟酰胺的50+防晒霜对面部黄褐斑和光老化相关色素沉着的影响:一项使用线场共焦光学相干断层扫描的初步观察研究

2026-02-010
OAAI
Clinical and Instrumental Evaluation of the Anti-Aging Effectiveness of a Cream Based on Hyaluronic Acid and a Cream Based on Hyaluronic Acid and Vitamin C: A Prospective, Multicenter, 8-Week, Parallel-Group Randomized Study on 91 Subjects

基于透明质酸的面霜和基于透明质酸与维生素C的面霜的抗衰老效果的临床与仪器评估:一项对91名受试者进行的预期性、多中心、8周、平行组随机研究

2025-08-230
PRE
Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib plus aromatase inhibitors (P plus AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)

弥合真实世界研究(RWSs)与1线帕博西利联合芳香化酶抑制剂(P plus AI)在激素受体阳性(HR+)/人表皮生长因子受体2阴性(-)转移性乳腺癌(mBC)中的随机对照试验(RCTs)之间的差距

2024-09-010
PRE
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials

延长芳香化酶抑制剂治疗激素受体阳性乳腺癌的疗效: 基于文献的随机试验荟萃分析

BREAST
IF7.9
2019-08-0113
PREAI
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
2014-12-0225
OAAI